All In Biotech

Drug Trial Radar · NCT04746924

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 669 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

669

Actual

Start

May 24, 2021

Primary completion

May 30, 2025

Study completion Mar 18, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Non-small Cell Lung Cancer
  • NSCLC

Interventions

  • TislelizumabDrug

    Tislelizumab is a monoclonal antibody formulated for intravenous injection.

  • OciperlimabDrug

    Ociperlimab is a monoclonal antibody formulated for intravenous injection.

  • PembrolizumabDrug

    Pembrolizumab is a monoclonal antibody formulated for intravenous injection.

  • PlaceboDrug

    Placebo infusions will consist of a sterile, normal saline solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Arms A and BTime frame: From randomization until the end of the study. Maximum time on study was 45.0 months
  2. Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)Time frame: From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months.
  3. Safety Run-In Substudy: Serum Concentration of OciperlimabTime frame: Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment.

Locations

218 sites in 19 countries. Site status is shown where the registry gives one.

  • Providence Medical Foundation St Jude Heritage Healthcare

    Fullerton, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Ocala Oncology Center Pl Dba Florida Cancer Affiliates Ocala

    Ocala, Florida

  • Advent Health Cancer Institute

    Orlando, Florida

  • Goshen Center For Cancer Care

    Goshen, Indiana

  • Baptist Health Lexington

    Lexington, Kentucky

  • University Medical Center New Orleans West Jefferson Medical Center

    New Orleans, Louisiana

  • Metro Minnesota Community Oncology Research Consortium (Mmcorc)

    Saint Paul, Minnesota

  • West Penn Hospital

    Pittsburgh, Pennsylvania

  • Centro Medical Austral

    Buenos Aires, Argentina

  • Centro Para La Atencion Del Paciente Oncologico (Caipo)

    San Miguel de Tucumán, Argentina

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • Northern Cancer Institute

    St Leonards, New South Wales, Australia

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Pindara Private Hospital

    Benowa, Queensland, Australia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Mater Cancer Care Centre

    South Brisbane, Queensland, Australia

  • John Flynn Private Hospital

    Tugun, Queensland, Australia

  • Lyell McEwin Hospital

    Elizabeth Vale, South Australia, Australia

  • Ballarat Health Services

    Ballarat, Victoria, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Western Health Sunshine Hospital

    St Albans, Victoria, Australia

  • St John of God, Murdoch

    Murdoch, Western Australia, Australia

  • Instituto Dor de Pesquisa E Ensino Distrito Federal

    Brasília, Brazil

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Brazil

  • Centro de Pesquisas Oncologicas Cepon

    Florianópolis, Brazil

  • Cancer Institute of Ceara

    Fortaleza, Brazil

  • Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia

    Santo André, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Beijing Chao Yang Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Army Military Medical University

    Chongqing, Chongqing Municipality, China

  • Daping Hospital, Third Military Medical University

    Chongqing, Chongqing Municipality, China

  • Chongqing University Three Gorges Central Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China

Showing 40 of 218 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.